BioSpace News Archive

Olympus announced today the FDA clearance of the new EVIS X1 endoscopy system, along with two compatible gastrointestinal endoscopes: the GIF-1100 gastrointestinal videoscope.

Cyclo Therapeutics, Inc. today announced that it has closed a private placement of its securities with Rafael Holdings, Inc. (NYSE:RFL) (“Rafael”) for the purchase of 2,514,970 shares of common stock and warrants.

Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an agreement with IMP Clinical Supply Services (“IMP”).

Fractyl Health announced today that it will be presenting updates on its Revita ® and Rejuva ® programs at several upcoming medical congresses in May 2023.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it received a new $10 million grant from the Bill & Melinda Gates Foundation to support Vir’s novel T cell vaccine development program.

Centinel Spine®, LLC announced record full-year 2022 performance and a top position in the TDR market.

CSL Vifor today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis (FSGS) from its partner Travere Therapeutics.

Strata Oncology, Inc. announced it received honorable mention in the health category of Fast Company’s 2023 World Changing Ideas Awards for the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit.

Miach Orthopaedics, Inc., a privately held company dedicated to developing bio-engineered surgical implants for connective tissue restoration, announced initiation of the Bridge Registry Post-Market Study of the company’s Bridge-Enhanced ACL Restoration Implant for anterior cruciate ligament tears.

Elixir Medical, a developer of breakthrough cardiovascular technologies, announced that data from its BIOADAPTOR RCT randomized controlled trial, an international, multicenter, single-blind study enrolling 445 patients will be presented at the EuroPCR conference in Paris.